Baldo Scassellati Sforzolini, MD, PhD, MBA: Expanding Nemolizumab’s Access
Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.